Results for the substance polatuzumab vedotin

Polatuzumab vedotin is a medication used in the treatment of certain types of non-Hodgkin lymphoma, such as diffuse large B-cell lymphoma (DLBCL).
It is a monoclonal antibody conjugated with a cytotoxic agent that works by targeting and destroying cancer cells expressing the CD79b protein.

The medication is administered intravenously, usually in combination with other chemotherapy therapies, to enhance treatment efficacy.
Polatuzumab vedotin helps reduce tumor size and slow disease progression, providing a therapeutic option for patients with advanced or relapsed lymphoma.

Common side effects include fatigue, nausea, diarrhea, peripheral neuropathy, and decreased blood cell counts.
In rare cases, severe adverse effects may occur, such as serious infections, liver toxicity, or allergic reactions.

It is essential for patients to be closely monitored during treatment and to inform their doctor of any unusual symptoms.
Polatuzumab vedotin should be administered under the supervision of an oncology specialist, and patients must strictly adhere to the treatment schedule.